{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:15:02Z","timestamp":1785788102389,"version":"3.56.0"},"reference-count":15,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The Infectious Diseases Society of America (IDSA) recommends a single dose of an aminoglycoside for uncomplicated cystitis caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales (ESBL-E) and difficult-to-treat Pseudomonas aeruginosa. However, there is very little recent clinical evidence to support this recommendation. The objective of this study was to evaluate the safety and efficacy of a single-dose aminoglycoside for cystitis caused by ESBL-E or Pseudomonas aeruginosa. This was a multicenter, retrospective, cohort study. Patients who received \u22653 days of standard of care were compared to patients who received a one-time dose of an aminoglycoside with or without a short course of effective therapy before. The primary outcome was the rate of relapse defined as requiring escalation of antibiotics or starting new antibiotic therapy within 14 days after the completion of antibiotics. A total of 66 patients were included in this study, with 33 patients in each arm. There were more males and complicated cystitis patients in the standard-of-care group. There was no difference found in the rate of relapse. The length of stay was significantly shorter in the aminoglycoside group (4.5 \u00b1 4.4 days vs. 14.1 \u00b1 10.1 days, p &lt; 0.0001). A one-time dose of an aminoglycoside did not increase the risk of relapse and was associated with a shorter length of stay when used to treat cystitis caused by ESBL-E or Pseudomonas aeruginosa.<\/jats:p>","DOI":"10.3390\/antibiotics13060552","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T10:41:03Z","timestamp":1718275263000},"page":"552","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Outcomes in Patients Who Received a One-Time Aminoglycoside Dose for Extended-Spectrum Beta-Lactamase-Producing Enterobacterales or Pseudomonas aeruginosa Cystitis"],"prefix":"10.3390","volume":"13","author":[{"given":"Kelsey","family":"Bouwman","sequence":"first","affiliation":[{"name":"Department of Pharmacy, ECU Health Medical Center, Greenville, NC 27834, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"George","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, ECU Health Medical Center, Greenville, NC 27834, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1086\/671740","article-title":"Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000\u20132009","volume":"34","author":"Zilberberg","year":"2013","journal-title":"Infect. Control. Hosp. Epidemiol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Aitken, S.L., Bonomo, R.A., Mathers, A.J., van Duin, D., and Clancy, C.J. (2023). Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin. Infect. Dis., ciad428.","DOI":"10.1093\/cid\/ciad428"},{"key":"ref_3","unstructured":"Macrobid (2008). Package Insert, Procter and Gamble Pharmaceuticals."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jama.2018.3627","article-title":"Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial","volume":"319","author":"Huttner","year":"2018","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1001\/archinte.167.20.2207","article-title":"Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women","volume":"167","author":"Gupta","year":"2007","journal-title":"JAMA Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1128\/AAC.02897-15","article-title":"Antibiotic Resistance among Urinary Isolates from Female Outpatients in the United States in 2003 and 2012","volume":"60","author":"Sanchez","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_7","unstructured":"Bactrim (2013). Package Insert, Mutual Pharmaceutical Company."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e00749-17","DOI":"10.1128\/mBio.00749-17","article-title":"Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene","volume":"8","author":"Ito","year":"2017","journal-title":"mBio"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/650482","article-title":"Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America","volume":"50","author":"Hooton","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1017\/ash.2022.317","article-title":"Three-day ceftriaxone versus longer durations of therapy for inpatient treatment of uncomplicated urinary tract infection","volume":"2","author":"Elajouz","year":"2022","journal-title":"Antimicrob. Steward. Healthc. Epidemiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e02165-18","DOI":"10.1128\/AAC.02165-18","article-title":"A Systematic Review of Single-Dose Aminoglycoside Therapy for Urinary Tract Infection: Is It Time To Resurrect an Old Strategy?","volume":"63","author":"Goodlet","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","first-page":"394","article-title":"Single-shot vs conventional therapy with amikacin for treatment of uncomplicated urinary tract infections: A multicenter study","volume":"5","author":"Rocca","year":"1986","journal-title":"Chemioterapia"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Jenrette, J.E., Coronato, K., Miller, M.A., Molina, K.C., Quinones, A., and Jacknin, G. (Acad. Emerg. Med., 2024). Prospective evaluation of single-dose aminoglycosides for treatment of complicated cystitis in the emergency department, Acad. Emerg. Med., early view.","DOI":"10.1111\/acem.14886"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1128\/JCM.01121-14","article-title":"When does 2 plus 2 equal 5? A review of antimicrobial synergy testing","volume":"52","author":"Doern","year":"2014","journal-title":"J. Clin. Microbiol."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/6\/552\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:57:45Z","timestamp":1760108265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/6\/552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["antibiotics13060552"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13060552","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]}}}